NFL Biosciences SA (EPA:ALNFL)

Market Cap	17.36M
Revenue (ttm)	46.00
Net Income (ttm)	-2.08M
Shares Out	12.67M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,945
Average Volume	70,711
Open	1.400
Previous Close	1.370
Day's Range	1.358 - 1.466
52-Week Range	1.050 - 2.740
Beta	1.25
RSI	61.21
Earnings Date	Mar 28, 2025

About ANSYS

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 5
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNFL

Financial Performance

In 2024, NFL Biosciences's revenue was 46, a decrease of -99.98% compared to the previous year's 200,011. Losses were -2.08 million, -44.44% less than in 2023.